Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors
This study aims at identifying molecular biomarkers differentiating responders and non-responders to treatment with Tumor Necrosis Factor inhibitors (TNFi) among patients with axial spondyloarthritis (axSpA). Whole blood mRNA and plasma proteins were measured in a cohort of biologic-naïve axSpA patients (n = 35), pre and post (14 weeks) TNFi treatment with adalimumab. Differential expression analysis was used to identify the most enriched pathways and in predictive models to distinguish responses to TNFi. A treatment-associated signature suggests a reduction in inflammatory activity. We found transcripts and proteins robustly differentially expressed between baseline and week 14 in responders. C-reactive protein (CRP) and Haptoglobin (HP) proteins showed strong and early decrease in the plasma of axSpA patients, while a cluster of apolipoproteins (APOD, APOA2, APOA1) showed increased expression at week 14. Responders to TNFi treatment present higher levels of markers of innate immunity at baseline, and lower levels of adaptive immunity markers, particularly B-cells. A logistic regression model incorporating ASDAS-CRP, gender, and AFF3, the top differentially expressed gene at baseline, enabled an accurate prediction of response to adalimumab in our cohort (AUC = 0.97). In conclusion, innate and adaptive immune cell type composition at baseline may be a major contributor to response to adalimumab in axSpA patients. A model including clinical and gene expression variables should also be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Biomolecules - 14(2024), 3 vom: 21. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sobral, Daniel [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 30.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/biom14030382 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370303377 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370303377 | ||
| 003 | DE-627 | ||
| 005 | 20240331001625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biom14030382 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM370303377 | ||
| 035 | |a (NLM)38540800 | ||
| 035 | |a (PII)382 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sobral, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This study aims at identifying molecular biomarkers differentiating responders and non-responders to treatment with Tumor Necrosis Factor inhibitors (TNFi) among patients with axial spondyloarthritis (axSpA). Whole blood mRNA and plasma proteins were measured in a cohort of biologic-naïve axSpA patients (n = 35), pre and post (14 weeks) TNFi treatment with adalimumab. Differential expression analysis was used to identify the most enriched pathways and in predictive models to distinguish responses to TNFi. A treatment-associated signature suggests a reduction in inflammatory activity. We found transcripts and proteins robustly differentially expressed between baseline and week 14 in responders. C-reactive protein (CRP) and Haptoglobin (HP) proteins showed strong and early decrease in the plasma of axSpA patients, while a cluster of apolipoproteins (APOD, APOA2, APOA1) showed increased expression at week 14. Responders to TNFi treatment present higher levels of markers of innate immunity at baseline, and lower levels of adaptive immunity markers, particularly B-cells. A logistic regression model incorporating ASDAS-CRP, gender, and AFF3, the top differentially expressed gene at baseline, enabled an accurate prediction of response to adalimumab in our cohort (AUC = 0.97). In conclusion, innate and adaptive immune cell type composition at baseline may be a major contributor to response to adalimumab in axSpA patients. A model including clinical and gene expression variables should also be considered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a RNA-seq | |
| 650 | 4 | |a TNF inhibitor (adalimumab) | |
| 650 | 4 | |a adaptive immune system | |
| 650 | 4 | |a axial spondyloarthritis | |
| 650 | 4 | |a disease activity | |
| 650 | 4 | |a innate immune system | |
| 650 | 4 | |a peripheral blood | |
| 650 | 4 | |a proteomics | |
| 650 | 4 | |a treatment response | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Fernandes, Ana Filipa |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardes, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Patrícia |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Lagoas-Gomes, João |e verfasserin |4 aut | |
| 700 | 1 | |a Tavares-Costa, José |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, José A P |e verfasserin |4 aut | |
| 700 | 1 | |a Dias, João Madruga |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardo, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gaillard, Jean-Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Armengaud, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Benes, Vladimir |e verfasserin |4 aut | |
| 700 | 1 | |a Domingues, Lúcia |e verfasserin |4 aut | |
| 700 | 1 | |a Maia, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Branco, Jaime C |e verfasserin |4 aut | |
| 700 | 1 | |a Coelho, Ana Varela |e verfasserin |4 aut | |
| 700 | 1 | |a Pimentel-Santos, Fernando M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomolecules |d 2011 |g 14(2024), 3 vom: 21. März |w (DE-627)NLM228347106 |x 2218-273X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:3 |g day:21 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/biom14030382 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 3 |b 21 |c 03 | ||